Therapeutic Asset Ratings

502 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Autologous, Engineered T Cells Targeting Tp53 R175H Breast Cancer	AstraZeneca	P1	C (36)
Autologous, Engineered T Cells Targeting Tp53 R175H Non-Small Cell Lung Carcinoma	AstraZeneca	P1	C (36)
Autologous, Engineered T Cells Targeting Tp53 R175H Ovarian Cancer	AstraZeneca	P1	C (36)
AZD0240 Non-Small Cell Lung Carcinoma	AstraZeneca	P1	C (36)
azd0240: autologous, engineered t cells targeting kras g12d Non-Small Cell Lung Carcinoma	AstraZeneca	P1	C (36)
azd1043 Obesity Disorder	AstraZeneca	P1	C (36)
azd5335 Ovarian Cancer	AstraZeneca	P1	C (36)
Fpi-2053 Cancer	AstraZeneca	P1	C (36)
NT-112 Non-Small Cell Lung Carcinoma	AstraZeneca	P1	C (36)
Recombinant Human Hyaluronidase Cancer	AstraZeneca	P1	C (36)
Rilvegostomig Cancer	AstraZeneca	P1	C (36)
Durvalumab Hepatobiliary Cancers	AstraZeneca		D (30)
Tezepelumab Cardiovascular Disorder	AstraZeneca		D (30)
Trastuzumab Deruxtecan Adenocarcinoma	AstraZeneca		D (30)
Trastuzumab Deruxtecan Anal Carcinoma	AstraZeneca		D (30)
Trastuzumab Deruxtecan Urinary Bladder Carcinoma	AstraZeneca		D (30)
Trastuzumab Deruxtecan Gallbladder Cancer	AstraZeneca		D (30)
Trastuzumab Deruxtecan Gastrointestinal Stromal Tumor	AstraZeneca		D (30)
Trastuzumab Deruxtecan Head And Neck Cancer	AstraZeneca		D (30)
Trastuzumab Deruxtecan Lip And Oral Cavity Carcinoma	AstraZeneca		D (30)
Trastuzumab Deruxtecan Nasopharyngeal Carcinoma	AstraZeneca		D (30)
Trastuzumab Deruxtecan Digestive System Neuroendocrine Neoplasm	AstraZeneca		D (30)
Trastuzumab Deruxtecan Salivary Gland Cancer	AstraZeneca		D (30)
Trastuzumab Deruxtecan Sarcoma	AstraZeneca		D (30)
Trastuzumab Deruxtecan Testicular Cancer	AstraZeneca		D (30)

Showing 451 to 475 of 502 assets

PreviousPage 19 of 21Next